SGLT2 inhibitors have confirmed hypoglycemic effects with no risk of hypoglycemia; they can also reduce body weight and blood pressure, increase natriuresis and diuresis, and afford additional cardiovascular and renal protection (Bolinder et al., 2014; Neeland et al., 2016; Park et al., 2020). The gene discussed is SLC5A2; the disease is Hypoglycemia.